Month: December 2016

Blue Horseshoe Stocks: CNAT Recap & More

Conatus Pharmaceuticals, Inc. CNAT

We were fairly confident that at least one of the pharma news plays we put forth in yesterday’s premarket report would turn out a promising session, and CNAT definitely rose to the occasion.

We highlighted it, of course, because of a big collaboration and licensing deal for one of the company’s drugs, which adds a quick $50M cash to the books almost immediately, and even more down the road.

After gapping up considerably in the premarket, the stock underwent a dip-and-rip scenario which carried it to a daily low of 4.27 before it pushed its way up to a high of 5.50. That marked a solid intraday upswing of 29% and came on four times the three-month average volume.

ACADIA Pharmaceuticals, Inc. ACAD

ACAD was the other play off of our pharma watchlist that provided us with significant opportunities, which were even bigger than the previously mentioned stock.

We offered an options idea, the ACAD Weekly $28-31 Calls, and all but a couple sets of contracts in that range produced respectable intraday moves.

$28 Calls – Range: .70-1.66 – Max Gain: 137%
$28.50 Calls – Range: .59-1.40 – Max Gain: 137%
$29 Calls – Range: .40-.80 – Max Gain: 100%
$29.50 Calls – Range: .30-.70 – Max Gain: 133%
$30 Calls – Range: .18-.50 – Max Gain: 178%

______

NIKE, Inc. NKE – Fresh Options Idea

NKE is coming off a post-market earnings beat yesterday, so we want to enter an idea into the logs for this situation.

We’re going to be monitoring the activity in the NKE Weekly $52.50-54 Calls for possible daytrades and/or swing trades into the end of the week.

Extended Watchlist:
LEOM, MMEG, INO, ESEA, SINO, DCIX, DRYS, HIMX(Bottom-Watch)

Blue Horseshoe Stocks: Pharma News Watchlist & More

Pharma News Watchlist:

We’ve got a trio of pharma plays to add to our watchlist on the heels of fresh news releases for each of them this morning. Each stock is gapping up significantly in the premarket, and we’ll be waiting in the wings once the session commences to see if we can use the resulting activity to our advantage.

Akebia Therapeutics, Inc. AKBA – Per the newly announced agreement out today, AKBA has entered into a Collaboration and License Agreement to carry forward with the development of one of its treatments. The deal comes with an immediate payment of $125M, a cash infusion that represents roughly 40% of the company’s total market cap as of yesterday.

______

ACADIA Pharmaceuticals, Inc. ACAD – In the case of ACAD, we’ve gotten word of positive top-line results in a Phase II study it was conducting on the company’s Alzheimer’s drug.  To leverage the present activity to our advantage here, we’re going to track the ACAD Weekly $28-31 Calls. (>>View PR)

_______

Conatus Pharmaceuticals, Inc. CNAT

Here we have another collaboration and licensing deal, for CNAT’s liver drug, which is going to be bringing a $50M cash infusion Conatus’ way. That’s just the initial tranche, with more payments to follow as outlined in the relevant filing (>>View 8-K)

Globalstar, Inc. GSAT

We put GSAT on watch as a possible momentum play in yesterday morning’s premarket report, and while it didn’t break out in a major way, it did continue the trend of solid upward momentum that has been observed in recent sessions. From an early low of 1.25, the stock ran as high as 1.60; a 28% pop.

The performance, while not astronomical, was certainly enough to hold our interest in continuing to monitor GSAT’s activity moving forward.

Cellectar Biosciences, Inc. CLRB – Reminder

We just wanted to take a quick moment to reiterate a possible bottom-play selection we made last week in the form of CLRB. We’re still tracking this one, and think it has a good chance to produce a recovery, possibly following the holiday break. So we’re going to want to leave a space on our watch screens reserved for CLRB in the days and weeks ahead.

Extended Watchlist:
AXPW, CAPS, MFST, ENDV, ETRM, EXAD

Blue Horseshoe Stocks: LLY Options Recap & More

Eli Lilly and Co. LLY – Options Update

In our premarket report on Friday morning, we finished off with a set of fresh options ideas for the LLY chain, and were met with nice gain opportunities on the day on all accounts.

In addition to a daytrading idea with the LLY Weekly $72 and $72.50 Calls, which worked out in spades, we also got some really good initial movement out of the longer term target we put forth, the 01/20 $75 Calls.

Weekly $72 Calls – Range: .20-1.25  – Max Gain: 475%
Weekly $72.50 Calls – Range: .15-.80  – Max Gain: 433%
1/20 $75 Calls – Range: .77-1.39  – Max Gain: 81%

We offer congratulations to anyone who benefited from the short-term ideas, and we’ll be sure to stay on the trail of those 01/20 $75 Calls in the weeks ahead.

Globalstar, Inc. GSAT

We caught a glimpse of GSAT on our scanner this morning and feel it’s worthy of mentioning, based on a number of factors. Last week, the moves that the stock had been making off of its recent relative lows in the low .70-range began to increase.

On Thursday, the stock bullishly breached its 50DMA, culminating in a huge spike in volume on Friday. Roughly six times the monthly average trading volume accompanied a break of the dollar mark. We’re going to put this on watch as a possible momentum play.

AmpliPhi BioSciences, Inc. APHB

Speaking of bottom-bouncers, APHB cropped on our scan as well, and it has a look of high potential as it’s coming up off of its recently established annual lows.

In addition, there’s a gap to fill on the chart to the upside, and with the stock already trading up in the premarket, that’s a real possibility here. With such a ripe chart, we’ll be very interested to follow APHB’s activity out of the gate this morning.

Extended Watchlist:
NHMD, ECPN, EVOK, APTO, ANY(Bottom Play)